Lu Qingguo, representative of the National People's Congress: Promoting the production and circulation of Chinese medicine formula particles and the comprehensive utilization of slag

2020 National Conference officially opened today, the National People's Congress representative, Chenguang Biotech Group Chairman Lu Qingguo in view of the existing problems in the Chinese medicine formula particle industry, proposed to promote the production and circulation of Chinese medicine formula particles and comprehensive utilization of slag, and constantly improve the competitive advantage of Chinese formula particlesChinese medicine is the treasure of the Chinese nation and an important carrier of the broad and profound ness of Chinese civilizationChinese medicine, as China's unique health resources, huge potential economic resources, scientific and technological resources with original advantages, excellent cultural resources and important ecological resources, plays an important role in economic and social developmentEspecially during the outbreak of the new coronavirus, in the treatment of infected people adhere to the Chinese and Western medicine, and actively use chinese medicine treatment methods, the patient's condition relief, treatment, after the treatment has played a very important roleAt present, the overall scale of China's Chinese medicine industry has exceeded 800 billion yuan, of which the scale of Chinese medicine tablets has exceeded 200 billion yuan, the size of the national Chinese medicine formula particles has been close to 20 billion yuanSince the pilot work of Chinese medicine formula particles in 2001, after 19 years of rapid development, has become an indispensable force in the Chinese medicine industry, clinically because of its easy to take, easy to carry the advantages, doctors and patients are willing to choose, use, for China's public health cause has made a great contributionEspecially after the release of the Measures for the Management of Chinese Medicine Formula Particles (Draft for Comments) in 2015, enterprises and research institutions were encouraged to carry out research on the uniform standards of Chinese medicine formula particles, and the first batch of 160 Chinese medicine formula particle standards will be published in the first phase in 2019, which will indicate that the Chinese medicine formula particle industry can move towards a more standardized and healthy directionHowever, there are still some problems in the Chinese medicine formula particle industry: the Interim Regulations on the Management of Chinese Medicine Formula Particles issued in 2001 put forward three requirements for the pilot enterprises, one of which is that the pilot enterprises must develop more than 400 varieties, when only 6 of the formula particle pilot enterprisesAs a result of this regulation of historical evolution, as of February 2020, although the country has obtained various types of Chinese medicine formula particle pilot qualification of enterprises have more than 60, but each production enterprises are producing more than 400 kinds of formula particlesEach enterprise produces hundreds of formula particles, caused the following problems can not be solved: First, can not establish the enterprise can control the raw materials cultivation base, resulting in the quality of Chinese medicine raw materials is not easy to control, raw material prices rise and fall sharply; Tens of millions, every enterprise to do so, will cause a great waste of social resources; third, the production enterprises repeated production, resulting in the formulation of particulate varieties can not use the most advanced technology, technology and management, resulting in waste of resources;also after a large number of studies show that the chinese medicine formula particles in the residue of many non-extraction of complete fat-soluble active ingredients, such as: dansan dansan ketones are fat-soluble ingredients, dansan formula particles in the production process only water extraction process, resulting in a large number of dansin ketones remaining in the slag; Formula particle process only extracted a small amount of water-soluble ingredients, there are still more than 60% of acidpolysacs exist in the slag; After rough statistics, the annual output of Chinese medicine formula grain yield of large varieties, the annual use of Chinese herbal medicine volume of nearly tons, with the development of the industry every year the use of Chinese herbal medicine is still expanding, the output of slag is also increasing year by yearHowever, because the current manufacturers are distributed throughout the country, can not make the slag centralized treatment, not only make it difficult to achieve comprehensive utilization of slag, manufacturers need to pay to complete the slag treatment, resulting in a great waste of social resourcesthe existence of the above problems, resulting in social resources, human, material and medicinal resources waste huge, without twisting it will be difficult to enhance the competitive advantage of Chinese formula particles1With the end of the pilot system of Chinese medicine formula particles, it is recommended that the State Drug Administration, on the basis of open standards and uniform standards, encourage the production and circulation of various formula grain varieties from a policy2, recommended that the State Drug Administration to introduce policies to encourage each production enterprise, according to their own strength, to do several of the best Chinese medicine particle productsFrom the construction of raw material base, to the production process research, management and product sales, bigger and stronger3, recommended that the State Drug Administration to introduce relevant incentives to support Chinese medicine formula granule enterprises to do a good job of classification of slag, and comprehensive use of research, while the introduction of incentives in the pharmaceutical, food, feed and other industries to apply policies, reduce restrictions.